Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody C"C chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company was incorporated in 2016 and is based in New York, New York.
Frequently asked questions
What sector does Regnum Corp (RGMP) operate in?
Regnum Corp belongs to the Healthcare sector and operates in the Entertainment industry.
What is Regnum Corp (RGMP) current stock price?
As of the latest data, Regnum Corp stock price is $0.00, with a previous close of $0.00.
What is Regnum Corp (RGMP) current market capitalization?
Regnum Corp market cap is approximately 2.29 thousand.
What is Regnum Corp (RGMP) Earnings Per Share (EPS)?
The trailing EPS is -$0.03.
Does Regnum Corp (RGMP) pay dividends?
No. Regnum Corp does not pay a dividend.
What is Regnum Corp (RGMP) beta (volatility) score?
Regnum Corp has a beta of -1.023, indicating lower volatility than the overall market.